Table 4 Analysis of staging related to SPAG5 and NuMA mRNA expression. Clinical stage was determined by the TNM system (tumor size, lymph node involvement, metastasis). According to AJCC guideline, the molecular stage was defined using TNM, tumor grade and ER, PR and HER2 status

SPAG5

Clinical stage

Stage I

12(30)

102.71

2

51.35

4.50

.018

Stage II

19(47.5)

Stages III and IV

9(22.5)

Molecular stage

Stage I

30(75)

2.74

2

1.37

.09

.90

Stage II

5(12.5)

Stages III and IV

5(12.5)

Molecular subtypes

Luminal A

12(30)

34.11

3

11.37

.83

.48

Luminal B

22(55)

HER2 positive

2(5)

Basal-like

4(10)

NuMA

Clinical stage

Stage I

12(30)

4.03

2

2.02

.32

.72

Stage II

19(47.5)

Stages III and IV

9(22.5)

Molecular stage

Stage I

30(75)

8.73

2

4.36

.72

.49

Stage II

5(12.5)

Stages III and IV

5(12.5)

Molecular subtypes

Luminal A

12(30)

44.97

3

14.99

2.88

.049

Luminal B

22(55)

HER2 positive

2(5)

Basal-like

4(10)